This post is sponsored by Lemonade. When it comes to travel, I tell all my close friends to hope for the best and prepare for ...

Shares in 23andMe are currently trading at around $3.40, giving it a valuation of just under $82 million. The company went ...

Here's the latest M&A news and auction block updates. Among the most watched items: a TikTok deal is still in flux.

Me still merchandises its ancestry, health analysis, and the Total Health annual package on a scale from $99 to $999 annually. Lemonaid entered the hot GLP-1 prescribing and support business in 2024, ...

Investing.com -- Genetic testing firm 23andMe is reportedly considering the sale of its telehealth division, Lemonaid Health, according to Business Insider. The company, which has faced financial ...

23andMe has been testing the waters for a buyer for Lemonaid Health, the virtual-care business it bought in 2021 for $400 million in cash and stock, people with knowledge of the efforts told BI.

Struggling genetic testing 23andMe is looking for a buyer for the virtual care business it acquired in 2021, Business Insider has learned.

The struggling health company bought the virtual-care startup Lemonaid in 2021 for $400 million. 23andMe's stock plummeted after a 2023 data breach exposed millions of customer accounts.